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ABSTRACT 
 
 
 
BACKGROUND: Chronic inflammation has been implicated in the pathogenesis of 
many chronic diseases, including colorectal cancer.  Obesity has been identified as a risk 
factor for colorectal cancer via induction of a chronic state of low-grade bowel 
inflammation due to excessive release of inflammatory cytokines such as C-Reactive 
protein (CRP) by adipocytes.  Prior studies have produced evidence of positive 
associations between CRP and colon cancer risk but none to date have assessed if 
elevated CRP is an independent risk factor when controlling for obesity.  Also, 
controversy exists about which measure of adiposity best predicts risk of colon cancer.  
METHODS: We examined these questions using the National Health and Nutrition 
Examination Survey III (NHANES III) database linked to the National Death Index.  In 
addition to CRP level, we studied the following four adiposity measures: body mass 
index, waist circumference, waist-to-hip ratio, and a new index developed by the NIH 
that stratifies BMI according to waist circumference.  Outcome variables were: all-cause, 
colorectal cancer, other obesity related cancers, and all other causes.  Dichotomous and 
Polytomous Logistic Regression were performed.  RESULTS:  CRP levels showed 
positive but weak correlations with adiposity measures.  In the age-adjusted and 
multivariate Dichotomous Logistic Regression analyses, elevated CRP level was 
significantly associated with all-cause mortality (OR=1.63 95% CI 1.40-1.91; and 
OR=1.32, 95% CI 1.08-1.61; respectively.)  Using age-adjusted and multivariate 
Polytomous Logistic Regression, elevated CRP level was associated with mortality from 
colorectal cancer (OR=2.72, 95% CI 1.30-5.72; OR= 2.44, 95% CI 1.20-4.94; 
respectively.)  OR estimates did not change appreciably when adiposity measures were 
included in multivariate models.  Further, none of the body measures of adiposity were 
significantly associated with cause-specific death in either age-adjusted or multivariate 
analyses. CONCLUSIONS:  Our findings suggest that CRP may be an independent risk 
factor for all-cause and, more so, for colorectal cancer mortality.  We speculate that the 
surprising effects related to body measures of adiposity may reflect misclassification 
related to the single baseline obesity measurement, taken during 1988-94, in light of the 
obesity epidemic that emerged during the follow-up time period.  Further investigation of 
this relationship is warranted to determine of elevated CRP remains an independent risk 
factor when longitudinal adiposity history is known.   
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1.0  INTRODUCTION 
 
 
1.1 Cancer  
Cancer is a group of diseases characterized by uncontrollable cell growth and spread of 
abnormal cells (ACS, 2008.)  Cancer is the second most common cause of death in the 
United States, accounting for 1 out of every 4 deaths (ACS, 2008.)  1,437,180 new 
cancer cases were diagnosed in the United States and 565,650 Americans died from 
cancer in 2008 alone (ACS, 2008.)  The impact of cancer on society is seen not only in 
the rates of morbidity and mortality of Americans but also in terms of economic 
consequences as well.  The National Institutes of Health estimates that the overall cost of 
cancer in 2007 was $219 billion dollars, with $89.0 billion used for direct medical costs, 
$18.2 billion from indirect morbidity costs, and $112.0 billion from indirect mortality 
costs (ACS, 2008.)  To help relieve the heavy burden, the U.S. Department of Health 
and Human Services identified cancer as a primary focus area for research and programs 
to improve health in the country (DHHS, 2000.) 
Overall cancer incidence and death rates have decreased steadily in the United 
States over the past few decades due to better screening techniques and advances in 
treatment methodologies.  Yet, it may be possible to prevent or delay certain cancers as 
it has been estimated that two-thirds of cancers are caused by modifiable risk factors 
such as tobacco use, alcohol use, overweight, physical inactivity, and unprotected 
exposure to ultraviolet rays (ACS, 2008.)  Furthermore, overall rates of cancer are 
expected to rise as the population ages.  Also, there is some speculation that as more 
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people adopt habits and lifestyles which confer greater risk, cancer is expected to 
overtake cardiovascular disease as the leading cause of death worldwide by 2010 (IARC, 
2008.)  Hence, it is important that research on the modifiable risk factors and underlying 
mechanisms of cancer be advanced so that health professionals can develop effective 
practices to prevent and treat cancer. 
 
1.2 Inflammation and Cancer 
An emerging theory linking behavioral risk factors with cancer development postulates 
that chronic, systemic inflammation contributes to the carcinogenic process by 
promoting cellular injury and proliferation, processes that can produce a favorable 
environment for genetic mutations to occur (Helzlsouer et al., 2006.)  The link between 
cancer and inflammation was first postulated in 1863 by Virchow who speculated that 
the origin of cancer was at sites of chronic inflammation (Hong et al., 2007.)  Studies of 
chronic inflammation and cancer have provided promising evidence that individuals 
with inflammatory diseases are at greater risk for developing certain types of cancer 
specific to the site of inflammation, such as colorectal cancer among those with irritable 
bowel diseases, liver cancer among chronic Hepatitis C sufferers, and stomach cancer 
among those with chronic ulcers (Bernstein, 2006; Sherman, 2006; Schottenfeld et al., 
2006.)  Recent studies have shown that inflammatory proteins may induce repeated local 
cellular injury through oxidative damage which, in turn, may result in genetic mutations 
or disruption of the formation of proteins involved in DNA repair and apoptosis (Lu et 
al., 2006; Peisajovich et al, 2008; Heikkila et al., 2009.)  These findings suggest that 
chronic inflammation may play a causal role in malignancy as well as in progression. 
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A number of markers have been identified as useful tools to measure chronic 
systemic inflammation.  C-Reactive Protein (CRP), an acute-phase reactant produced by 
the liver and adipocytes, has emerged as a reliable, non-specific serologic marker of 
inflammation (Helzlsouer et al., 2006.)  CRP is an innate opsonin, a protein that 
recognizes microbes and other potentially harmful matter inside the body and promotes 
their uptake and destruction by immune cells (Peisajovich et al., 2008.)  CRP levels in 
the body may rise in response to many factors, including the presence of acute 
conditions such as burns and heart attacks or chronic conditions such as arthritis and 
diabetes.  There is also evidence of variation in CRP level due to polymorphisms in 
genes that code for CRP production (Black et al., 2004; Heikkila et al., 2009.)  The 
association of elevated CRP levels with outcomes such as cardiovascular disease, type II 
diabetes, and, most recently, certain types of cancer, has created growing interest in 
ascertaining how inflammation might contribute to etiology (Danesh et al., 2004; 
Peisajovich et al., 2008; Heikkila et al., 2009; Grootendorst et al., 2007.) 
Several different theories have been proposed to explain why high CRP levels 
are associated with increased risk for cancer incidence.  First, CRP could become 
elevated when the tissue surrounding a growing tumor becomes inflamed due to 
infringement upon the organ (Peisajovich et al., 2008.)  Second, CRP elevation could be 
related to immune system response to tumor antigens which may be reflected by 
elevated systemic inflammation (Balkwill et al., 2001.)  Another theory is that the 
production of inflammatory mediators such as prostaglandins or COX-2 by cancer cells 
may stimulate CRP production (Heikkila et al., 2007.)  Lastly, a rise in CRP also could 
be a response to pre-malignant lesions (Peisajovich et al., 2008.)  The temporal 
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significance of elevated markers of systemic inflammation has yet to be determined.  A 
number of prospective studies, however, collected baseline measurements of CRP 
several years before the diagnosis of cancer and have provided evidence that CRP levels 
were elevated before any measurable signs of cancer were detected (Helzlsouer et al., 
2006; Tsilidis et al., 2008.)  This finding suggests that CRP may be useful as a marker to 
identify individuals at risk for cancer.   
In addition, it has been postulated that C-reactive protein may have prognostic 
value as an indicator of mortality risk.  Several studies have demonstrated an association 
between elevated CRP and risk of overall mortality as well as cause-specific death from 
cardiovascular disease and cancer (Suleiman et al., 2006; Cae et al., 2007.)  In a cohort 
study conducted by Marsik et al. (2008) of almost 275,000 individuals, a 3.3 fold risk for 
all-cause death was found in individuals with the highest levels of CRP compared with 
individuals with the lowest level of CRP; a similar yet attenuated risk was noted for 
individuals with moderate levels of CRP compared to individuals with low CRP, 
indicating a dose-response relationship.   
The link between CRP and mortality has been seen in both short-term and long-
term prospective studies.  A study by Makita et al. (2008) following patients for a mean 
of only 2.7 years found an odds ratio of 2.26 for overall mortality among individuals 
with CRP levels greater than 1 mg/L.  Koenig et al. (2008) found significant associations 
between CRP levels greater than 3 mg/L and overall mortality (OR=1.88), 
cardiovascular disease mortality (OR=2.15) and cancer mortality (OR=1.74) for 
individuals with a mean follow-up time of 7.1 years.  Therefore, CRP shows promise as 
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a potential marker for predicting negative health outcomes in both short- and long-term 
prospective studies. 
 
1.3 Colorectal Cancer Burden 
Colorectal cancer (CRC) is the third most common cancer in the United States, with 
108,070 colon cancers and 40,740 rectal cancers documented in 2008 (ACS, 2008.)  An 
estimated 49,960 deaths among males and females resulted from colorectal cancer in 
2008, making it the second most lethal cancer in the United States following lung cancer 
(ACS, 2008.)  Colorectal cancer incidence and death has decreased during the last two 
decades, primarily due to better detection at early stages from increases in colonoscopy 
screening and improved treatment modalities.  A sharp increase in colorectal cancer, 
however, has been observed in rapidly developing countries and among migrant 
populations in the U.S., consistent with long-standing evidence that environmental and 
lifestyle factors to play a key role in colorectal carcinogenesis (Whittemore et al., 1990; 
IARC, 2008.) 
 
1.4 Behavioral Risk Factors and Mortality from Colorectal Cancer  
Several factors may increase the risk of developing and dying from colorectal cancer.  
Age is the most prominent risk factor for colorectal cancer, with over 90% of cases 
being diagnosed in people 50 years and older (ACS, 2008.)  Familial or personal history 
of colorectal cancer, polyps, or inherited genetic syndromes such as familial 
adenomatous polyposis or hereditary non-polyposis colorectal cancer may also be strong 
indicators of risk.  Personal history of chronic inflammatory bowel diseases such as 
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Irritable Bowel Syndrome and Crohns Disease also confers risk for colorectal cancer by 
increasing gut permeability to allow greater exposure of colonocytes to luminal antigens 
(Soderholm et al., 2004.)   
 From a population-based perspective, the majority of risk for colon cancer, 
however, has been attributed to modifiable risk factors such as obesity, physical 
inactivity, smoking, heavy alcohol consumption, a diet high in red meat and processed 
foods, and inadequate dietary fiber intake (Chao et al., 2005; Park et al., 2005; Frezza et 
al., 2006; ACS, 2008.)  These preventable risk factors play significant roles in the 
etiology of colorectal cancer, and it is projected that colorectal cancer rates will rise as 
the world realizes the consequences borne of the “Westernized” trend in globalization, 
which to date has been associated with concomitant increases in obesity and physical 
inactivity.   
 
1.5 Adiposity and Colorectal Cancer  
As mentioned, a key risk factor for colorectal cancer is obesity. A significant dilemma 
traditionally encountered in most studies of obesity and health outcomes is deciding 
which body measurement of adiposity best reflects risk of disease.  Dozens of studies 
have evaluated the relationship of various adiposity measures (i.e. body mass index, 
waist circumference, waist-to-hip ratio), finding a moderate positive relationship 
between increasing obesity and increasing risk of CRC incidence and mortality (Russo et 
al., 1998; Moore et al., 2004; MacInnis et al., 2006; Pischon et al., 2006; Larsson et al., 
2007; Wang et al., 2008.)  Odds ratios for obesity and development of or death from 
colorectal cancer ranged from 1.07 to 1.79, depending on the adiposity measure used 
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and the population under study (Larsson et al., 2007; Moghaddam et al., 2007; Wang et 
al., 2008.) Crude body weight and body mass index were more strongly related to CRC 
incidence and death in men than in women, while waist circumference and waist-to-hip 
ratio were more strongly correlated with CRC incidence and death among women than 
among men (Russo et al., 1998; Pischon et al., 2006; Larsson et al., 2007; Wang et al., 
2008.)  The relationship between adiposity and risk of colon cancer appears to be 
stronger with advancing age and among individuals with low levels of physical activity 
(Moore et al., 2004.)  No statistically significant relationships were found between 
adiposity measures and rectal cancer incidence or death among men or women 
(MacInnis et al., 2006; Pischon et al., 2006.)     
 Several hypotheses have emerged to explain the underlying mechanisms linking 
obesity with colorectal cancer.  Two schools of thought currently dominate the research: 
(1) hyperinsulinemia pathway, and (2) chronic bowel inflammation by release of 
inflammatory cytokines from visceral adipose tissue into the lumen of the bowel (Wisse, 
2004; Calabro et al., 2008; Kim K et al., 2008; Kim S et al., 2008.)  Adipose tissue was 
long thought to be a passive storage facility for excess calories within the body (Visser et 
al., 1999; Fantuzzi, 2005; Calabro et al., 2008), but recent research provides evidence 
that adipose tissue, particularly central fat, is an active participant in regulating 
endocrine and pathologic processes, including immunity and inflammation (Fantuzzi, 
2005; Calabro et al., 2008.)  Evidence has shown that adipose tissue regularly releases 
cytokines (referred to as adipocytokines in this situation) such as C-Reactive Protein 
(CRP), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-α), that create a 
chronic low-grade inflammatory environment in the body locations proximal to fat 
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cells (Visser et al., 1999; Khaodhiar et al., 2004.)  Furthermore, it has been observed that 
macrophages tend to accumulate in the adipose tissue of obese individuals, leading to an 
even greater inflammatory response by prompting an increase in adipocytokine secretion 
by fat calls (Gunter et al., 2006.)  Visceral adipose tissue, or fat cells that are located 
around the waist and in between abdominal organs, seems to be more active and release 
more cytokines than subcutaneous adipose tissue located in the extremities (Kim K et al., 
2008.)  Numerous studies have shown that higher adiposity measures correlate well with 
increased serum levels of inflammatory proteins (Fantuzzi, 2005; Kim K et al., 2008; 
Wee et al., 2008.)  Correlations were more remarkable when measures of visceral 
adiposity (i.e. waist circumference) were compared with inflammatory marker levels 
than when measures of systemic adiposity (i.e. body mass index) were analyzed (Park H 
et al., 2005; Kim S et al., 2008; Wee et al., 2008.)   
To illustrate the lability of this association, several prospective longitudinal 
studies on weight change and subsequent changes in inflammatory marker levels have 
produced evidence that those participants who lost weight concomitantly lowered their 
inflammatory marker levels and those who gained weight experienced an increase in 
their inflammatory marker levels (Fogarty et al., 2008; Kim K et al., 2008.)  Also, 
regular use of non-steroidal anti-inflammatory drugs has been shown to confer a 
markedly decreased risk of colorectal cancer, providing evidence that chemoprevention 
of bowel inflammation protects against colon carcinogenesis (IARC, 1997; Grau et al., 
2009.)  It is postulated that the chronic bowel inflammation induced by high visceral 
obesity may promote an environment in which cell growth becomes dysregulated 
  
9 
through oxidative DNA damage, eventually overriding apoptotic controls and increasing 
likelihood of carcinogenesis (Gunter et al., 2006.)  
 
1.6 C-Reactive Protein and Obesity 
C-Reactive protein has been found to be a very promising biomarker for studying the 
relationship between obesity and inflammation (Erlinger et al., 2004.)  Park et al. (2005) 
studied CRP levels in relation to several adiposity measures among Asian adults, finding 
that CRP levels correlated strongly with abdominal obesity (Spearman’s coefficient for 
waist circumference=0.75) and moderately with other measures of obesity (Spearman’s 
coefficient= 0.65 for crude weight, 0.69 for body mass index, and 0.68 for waist-to-hip 
ratio.)  C-reactive protein produced more significant correlations with adiposity 
measures than any other inflammatory markers evaluated in the study.  Similar yet 
divergent results for the correlation of CRP and obesity were concluded in a study of 
European adults by Rexrode et al. (2003.)  This study also found a direct positive 
relationship between CRP and obesity; however, the strongest correlation observed was 
between CRP and body mass index, possibly indicating a difference in risk between the 
two demographically diverse study populations. Overall, CRP proved to be a stronger 
correlate of obesity than all other inflammatory markers measured in these two studies.   
 
1.7 C-Reactive Protein and Colorectal Cancer 
 In addition to being a relatively consistent correlate of obesity, CRP has also 
been found to be a more highly associated marker for colorectal cancer risk than other 
inflammatory markers.  A study by Il'yasova et al. (2005) examined the associations of 
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several inflammatory markers (C-Reactive Protein, Interleukin-6, and Tumor Necrosis 
Factor-alpha) with the risk of site-specific cancers and found that the association of CRP 
with colorectal cancer was more precise than the other two markers.  Another study by 
Groblewska et al. (2008) found C-Reactive Protein to be a better predictor for colorectal 
cancer death than other inflammatory markers.  Results of these studies suggest that, to 
date, CRP may be the most useful inflammatory marker to study when assessing risk of 
colorectal cancer incidence and death. 
 
1.8 Conclusion 
Ample evidence has linked higher levels of both obesity and C-Reactive Protein to 
increased risk for colorectal cancer incidence and death.  Furthermore, C-Reactive 
Protein levels and adiposity measures have shown a moderate positive correlation, 
indicating that CRP may be linked with colorectal cancer through an obesity-induced 
inflammation pathway.  However, it remains unknown how the relationship between 
CRP and obesity measures indicate risk of mortality and colorectal cancer among the 
National Health and Nutrition Examination Survey III (NHANES III) participants.  Is 
CRP a risk factor for all-cause mortality, and more specifically death from colorectal 
cancer, independent of obesity?  It is hypothesized that NHANES III participants having 
C-reactive protein levels greater than 0.50 mg/dL will incur a greater risk of all-cause 
mortality and colorectal cancer mortality than participants with normal CRP values, and 
that this relationship will persist after adjustment for adiposity measures.  Using data 
from NHANES III and the National Death Index, this investigation aims to: 
(1) Describe demographic and lifestyle attributes of those with normal and 
elevated levels of serum C-Reactive Protein, 
  
11 
 
(2) Determine whether individuals with elevated C-Reactive Protein levels have 
a greater risk of all-cause mortality and death from colorectal cancer compared to 
individuals with normal CRP levels, and, 
 
(3) Assess whether the relationship between CRP and all-cause mortality and 
death from colorectal cancer is modified by controlling for different measures of 
obesity (body mass index, BMI-W, waist circumference, and waist-to-hip ratio.) 
 
 
2.0 METHODS 
 
2.1 Study Population  
We analyzed data from the National Health and Nutrition Examination Survey III 
(NHANES III), the seventh of a series of studies conducted by the National Center for 
Health Statistics designed to estimate the nation’s health status, assess the nationwide 
prevalence of risk factors for disease, and contribute to an understanding of disease 
etiology (NCHS, 1992; DHHS, 1996.)  The NHANES III sample population was 
carefully constructed as a complex multistage probability sample to represent the total 
civilian non-institutionalized US population aged 2 months and older (NCHS, 1992.)  
39,695 persons were selected from 81 primary sampling units to be interviewed and 
examined, with oversampling employed among the young, the elderly, and minorities to 
facilitate statistically-powered investigations of these subsamples.  In two stages 
conducted from 1988-1994, 33,994 people were interviewed (14% non-response) and, of 
these, 30,818 participated in intensive physical examinations and blood draws for 
laboratory measures (9% non-response) at the NHANES mobile examination center 
(Mohadjer et al., 1996.)  Additionally, because NHANES III was the first in the series 
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to investigate individuals older than 75 years of age, a new home examination technique 
was developed to minimize non-response among this population (NCHS, 1994.)  
Ultimately, 31,311 examinations were recorded in the NHANES III database, with due 
care being exercised on the part of medical examiners and laboratory personnel to ensure 
continuity of exam protocol and proper handling and storage of body fluid specimens 
(Gunter et al., 1990.)  NHANES III methodologies and study participants have been 
described in detail elsewhere (Mohadjer et al., 1996.) 
 
2.2 Sample Weights in NHANES III  
The complex multistage probability sample employed in NHANES III requires that 
statistical analyses take into account: differential probabilities of selections among 
subgroups, bias from non-response, and need to reflect the dimensions of target 
population make-up (Mohadjer et al., 1996.)  This adjustment is accomplished by 
assignment of multiple weights to each individual, thereby allowing generalization of 
findings to the U.S. population as a whole.  Sample weighting was carried out in three 
stages.  First, a basic weight was calculated to compensate for three factors: the 
individual’s age/sex/race-ethnicity domain, the density stratum, and the primary 
sampling unit (Mohadjer et al., 1996.)  Second, a weight was applied to account for non-
response (Figure 1) of individuals at both the interview and examination stages after 
allocating non-responding individuals to classes such as race/ethnicity, age, household 
size, and self-reported health status (NCHS, 1992.)  A third weight was applied to all 
survey participants based on post-stratification of the sample weights in accordance with 
1990 census bureau estimates of the U.S. population (Mohadjer et al., 1996.)  
  
13 
Combining the basic weight, non-response adjustment weight, and post-stratification 
adjustment weight with a 4th weight that compensated for differences between Phase 1 
(1988-1991) and Phase II (1991-1994) samples created the overall weight for each 
individual studied in NHANES III.  For the purposes of this investigation, final weight 
“Final MEC+Home exam” (SAS weight code wtpfhx6) was employed to individuals 
who were interviewed and examined either at the mobile examination center or at home, 
and who were surveyed during either phase of the sampling periods (Mohadjer et al., 
1996; DHHS 1996.)   
 
2.3 NHANES III database linked with the National Death Index  
In order to transform NHANES III from a cross-sectional study into a prospective study 
with an outcome endpoint, the National Center for Health Statistics linked the NHANES 
III database with mortality data records from the National Death Index (NDI) through 
December 31, 2000, resulting in a follow-up time for mortality status ranging from 6 to 
12 years (Madans et al., 2006; NCHS, 2005.)  This data linkage was performed through 
probabilistic matching, with one or more of these criteria sufficing to produce a match: 
(1) social security number, (2) first and last name, exact month of birth, year of birth 
within 1 year, (3) last name, first and middle initials, exact month of birth, year of birth 
within 1 year, (4) first and last name, exact month and day of birth, (5) last name, first 
and middle initials, exact month and day of birth, (6) first name, father’s surname, exact 
month and year of birth, and (7) for females only, first name, exact month and year of 
birth, and last name from the survey record matching the birth surname on the NDI 
record (NCHS, 2005.)  Mortality status of NHANES III participants could also be 
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determined if a death certificate was directly received by NCHS and matched with a 
NHANES III survey record based on name and other linkable information such as 
occupation (NCHS, 2006.)  We used the public data files accessible on the NCHS 
website which included information on follow-up eligibility status, mortality status, 
mortality status source (NDI or death certificate), person-months of follow-up time from 
interview and exam, and underlying cause of death (NCHS, 2006.)  Underlying cause of 
death was established through use of ICD-9 codes through 1998 and ICD-10 codes for 
1999-2000, but final cause of death data were organized via ICD-10 codes after 
adjusting for changes between the coding systems (NCHS, 2006.)  At the end of the 
follow-up period, 3,384 adult NHANES III participants were assumed to be deceased 
through NDI linkage (NCHS, 2005.) 
 
2.4 Eligibility Criteria 
Individuals in the NHANES III population were determined to be eligible for this study 
if they were 50 years of age or older, had a known mortality status, and had valid data on 
covariates and outcomes.  Values of “blank but applicable,” “blank,” and “I don’t know” 
were re-categorized as missing data.  From the initial NHANES III sample of 33,994, 
our study included 7,589 participants with valid baseline data, laboratory assay results 
for CRP,  and NDI mortality follow-up (Figure 1.)   
 
2.5 Study Groups 
This study compares two study groups: (1) individuals with a serum C-reactive protein 
(CRP) level of <.50 mg/dL (normal) and (2) individuals with a serum C-reactive 
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protein level of .50 mg/dL or greater (high.)  This cutoff point for normal versus high C-
reactive protein was employed in colon cancer studies conducted by Koike et al., (2008) 
and Shiu et al., (2008.)  C-reactive protein was measured during the NHANES III 
laboratory examination (DHHS, 2007.)  Serum C-reactive protein was analyzed using a 
fully automated Behring Nephelometer Analyzer System (Behring Diagnostics, Inc, 
Somerville, NJ.)  Extensive details about the specific methods for obtaining C-reactive 
protein levels for the NHANES III population are provided elsewhere (Gunter et al., 
1996.) 
 Participants were further classified according to three commonly used adiposity 
measures: body mass index (BMI), waist circumference (WC), and waist-to-hip ratio 
(WHR.)  We also employed an adiposity measure developed in 1998 by the National 
Heart, Lung, and Blood Institute that stratifies BMI categories by waist circumference, 
which we refer to as BMI-W (NHLBI, 1998; Figure 3.)  Body measurements were taken 
by trained NHANES III examiners using specified protocols (DHHS, 1996.)  Body mass 
index was calculated by dividing an individual’s weight in kilograms by height in meters 
squared.  Categorization of BMI in our study used standard breakdowns (NHLBI 1998), 
as follows: [1] normal (BMI 18.5-24.9), [2] overweight (BMI 25.0-29.9) and [3] obese 
(BMI 30.0+.)  Underweight individuals (BMI < 18.5) were excluded from analysis.  
Waist circumference was calculated by measuring the circumference of the abdomen in 
centimeters at the natural waist, around the bellybutton.  Per accepted criteria (NHLBI 
1998), waist circumference was classified as high if a male participant’s waist 
circumference measured >102 cm at the bellybutton or a female participants’ waist 
circumference measure >88 cm at the bellybutton.  Waist-to-hip ratio was calculated 
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by dividing the waist circumference in centimeters by the hip circumference (measured 
at the widest point of the hips) in centimeters.  A WHR greater than 1.0 was considered 
high for males and a WHR greater than 0.9 was considered high for females in this study 
(NHLBI, 1998.)  As depicted in Figure 3, BMI-W consists of five categories: [1-normal] 
BMI (18.5-24.9) and any waist circumference); [2-increased] BMI (25.0-29.9) and waist 
circumference (normal); [3-high] BMI (25.0-29.9) and waist circumference (high) or 
BMI (30.0-34.9) and waist circumference (normal); [4-very high] BMI (30.0-34.9) and 
waist circumference (high) or BMI (35.0-39.9) and any waist circumference); and [5- 
extremely high] BMI (40.0+) and any waist circumference. 
 
2.6 Outcomes 
Mortality status (i.e., dependent variable) was categorized according to two schemes: [1] 
alive and deceased from any cause, and [2] alive, deceased from colorectal cancer 
(CRC), deceased from other obesity-related cancers (oORC), and deceased from other 
causes (Other.)  The first scheme used the existing variable (mortstat) in the NDI-linked 
data file.  The second was created using ICD-10 codes for underlying cause of death 
(ucod_113) in the NDI-linked mortality data file.  The “alive” category was assigned 
when “mortstat”=0 and “ucod_113”=missing.  The “CRC” category was assigned to 
values where “mortstat”=1 and “ucod_113”=023, representing codes C18-C21 
(malignant neoplasms of the colon, rectum, and anus) in the ICD-10 codes (NCHS, 
2006.)  The “oORC” category was assigned to values where “mortstat”=1 and 
“ucod_113”= 025 (representing ICD-10 code C25, malignant neoplasms of the 
pancreas), 029 (representing ICD-10 code C50, malignant neoplasms of the breast), 
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031 (representing ICD-10 codes C54-55, malignant neoplasms of the corpus uteri and 
uterus), and 033 (representing ICD-10 cod C61, malignant neoplasms of the prostate; 
NCHS, 2006.)  The “Other” category was assigned to all values where “mortstat”=1 and 
“ucod_113” did not equal satisfy any of the above values (023, 025, 029, 031, 033.)   
 
2.7 Statistical Analyses  
All statistical analyses for this study were performed using SURVEY procedures 
available in SAS that incorporate essential survey information such as sample weights 
and stratification in analyses of data sets from complex multistage probability sampling 
techniques (An, 2002; Jones et al., 2006.)  Descriptive analyses (Aim 1) were performed 
for: age, gender, race/ethnicity, tobacco use, alcohol use, non-steroidal anti-
inflammatory drug use, and personal history of selected diseases in relation to CRP 
level, using t-tests for continuous data and chi-square tests for proportions.   
Mortality risk related to CRP level (Aim 2) was assessed by Dichotomous 
Logistic Regression for any cause of death, and, Polytomous Logistic Regression when 
multiple outcomes were studied (i.e., death from colorectal cancer, death for other 
obesity-related cancers, death from all other causes.)  We performed univariate, age-
adjusted and multivariate-adjusted odds ratios.  Separate analyses also were performed 
to examine the relationships between each of the adiposity measures and mortality risk.  
Covariates in the multivariate models are defined as follows:  Age was considered as a 
continuous variable in the multivariate model; Sex (male and female); Race/ethnicity 
(white non-Hispanic, black non-Hispanic, Mexican-America, and other.)This 
unconventional categorization comes from an existing variable in the original 
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NHANES survey, which purposefully oversampled Mexican-Americans;  Cigarette use 
(never, past, or current) according to answers given to the interview questions “Have you 
smoked more than 100 cigarettes in your lifetime?” and “Do you smoke now?”;  Alcohol 
use (never, past, or present) according to answers given to the interview questions “Have 
you had more than 12 alcoholic drinks in your lifetime?” and “Have you had more than 
12 alcoholic drinks within the last year?”; Physical Activity (more active than others, 
less active than others, or about the same as others) according to answers given to the 
question, “Compared to others your age, how would you rate your physical activity 
level?”; NSAID (yes or no) according to responses given to the question “Have you 
taken NSAIDS (aspirin, acetaminophen, ibuprofen, naproxen, etc.) within the last 
month?”; and, Personal History (yes, no) of cancer, cardiovascular disease, and diabetes 
was determined by responses to multiple questions specifically asking the respondents if 
they had been told by a doctor that they had cancer, cardiovascular disease (heart attack, 
congestive heart failure, etc), or diabetes.  To determine if observations regarding CRP 
held when controlling for body measures of adiposity (Aim 3), multivariate models 
defined above also included adiposity measures as covariates each in a separate analysis.   
 Results for all tests were considered statistically significant if p<0.05 or results 
within the confidence intervals (95%) did not include 1.0.  SAS 9.2 was used to perform 
all statistical analyses of NHANES III data in this investigation (SAS, 2008.) 
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3.0 RESULTS 
 
3.1 Participant Characteristics  
CRP Status.  Baseline characteristics for all eligible participants (n=7192) according to 
CRP level (Normal vs. High) are shown in Table 1.  Proportionately there were more 
females than males in the High-CRP group (29.34% vs. 23.29%, p=.0007.)  Non-
Hispanic blacks and Mexican Americans were more likely to be in the High-CRP group 
than Non-Hispanic whites and those categorized as "other" (38.01% and 28.93% vs 
25.75% and 21.76%, respectively, p<.0001.)  There were more current drinkers in the 
normal-CRP group than in the high-CRP group (77.12% vs. 22.88%p=.0020.)  
Participants in the normal CRP-group were much more likely than those in the high-CRP 
group to consider themselves physically active (44.23% vs. 28.79%, p<.0001.)  A 
marginal difference between the two groups was observed in relation to tobacco use 
(p=.06.)  Age, non-steroidal anti-inflammatory use, and having a personal history of 
cancer did not differ significantly between the two study groups.  
 Participants with higher levels of adiposity were more likely than those with 
normal weight to exhibit elevated CRP levels (Table 2.)  For example, participants with  
categorized as having normal or overweight BMI were more likely to have normal CRP 
levels compared to obese individuals (82.16%,, 75.13%, 40.14%, respectively, p<.001.) 
Participants in the high-CRP group were also more likely to have a high waist 
circumference and waist-to-hip ratio than did the normal-CRP group (p<.0001.)  
Similarly, participants with high-CRP levels were more likely to have higher-risk BMI-
W values (3-high, 4-very high, 5-extremely high) than the normal-CRP group.  
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Spearman’s correlation coefficients between CRP level and adiposity measures showed 
a weak positive relationship (Table 3.) 
All-Cause Mortality.  Table 4 illustrates patient characteristics according to mortality 
status based on the National Death Index linkage with the NHANES III database.  
Participants varied according to mortality status on almost all demographic and 
behavioral factors, as well as CRP level.  For example, males were more likely to be 
deceased than were females, and Non-Hispanic Whites and non-Hispanic Blacks were 
more likely to be deceased than Mexican Americans and those categorized as Other.  As 
expected, increasing age was a significant correlate of mortality with the youngest age 
group (50-54) being much less likely to be deceased than the oldest age group (80+; 
6.55% vs. 70.79%, respectively) with increasing mortality continually observed as age 
group increased (<.0001.) 
 With regard to CRP status and mortality, individuals with elevated CRP levels at 
baseline were much more likely to be deceased at the end of follow-up than those with 
normal CRP levels.  Participants who had classified themselves as current or past 
smokers were more likely to be deceased at end of follow-up (27.63% and 26.64% vs. 
22.35%, respectively), while current alcohol drinkers and those who reported taking 
NSAIDS within the last month were more likely to be alive at the end of follow-up.  
High physical activity rates also seemed to be protective against death.  Individuals 
reporting a personal history of cancer, cardiovascular disease and diabetes were more 
likely to die than those who had not. Contrary to evidence citing high adiposity as a risk 
factor for mortality, participants with high BMI, BMI-W, and waist circumference 
values were more likely to be alive at the end of follow-up than those with normal 
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values (p<.0001.)  Those with high waist-to-hip ratio values were slightly more likely to 
die by the end of follow-up than those with normal waist-to-hip ratio, but this 
relationship was not significant (p=0.72.)   
Cause-Specific Mortality.  In Table 5, we broke down mortality into four specific 
outcomes: Alive, Death from colorectal cancer (CRC), Death from other obesity-related 
cancers (Other-ORC), and death from all other causes (All Other Causes.)  Compared to 
females, males were more likely to die (p=.0408) from other obesity-related cancers 
(1.39% vs. 0.98%), colorectal cancer (0.64% vs. 0.53%) and all other causes (24.84% vs. 
21.96%.)  A higher proportion of Individuals with high-CRP died from CRC,  other 
obesity-related cancers and all other causes compared to those with normal CRP level 
(p<.0001.) Surprisingly, individuals with normal BMI, waist circumference, BMI-W, 
WHR levels tended to die in greater proportions than individuals with higher values 
(p<.0001.)  Although the specific cause of death varied somewhat according to tobacco 
smoking history (p=.0005), there appeared to be no coherent trend between ever use 
(past or current) and never use.  Similarly, cause of death varied according to alcohol use 
(p<.0001) but with no clear trend in relation to ever (past or current) versus never use. 
Current NSAID use was not associated with a consistently greater proportion of deaths 
across the types of deaths.  
 
3.2 CRP Status and Mortality Risk  
All-Cause Mortality.  Crude, age-adjusted, and multivariate-adjusted odds ratios for 
mortality are shown in Table 6.  Part A of Table 6 displays results from the conventional 
dichotomous logistic regression.  Compared to patients with normal CRP levels, those 
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with high CRP levels had an approximately 60% increase in risk of death as seen in both 
the crude and age-adjusted analyses.  This risk was attenuated to approximately a 30% 
increased risk of death after adjustment for the following suspected confounders: sex, 
age, race/ethnicity, tobacco use, alcohol use, physical activity level, NSAID use, and 
personal history of cancer, cardiovascular disease, or diabetes.  Analyses were conducted 
with each adiposity measure added as a covariate in separate multivariate models.  Odds 
Ratios for mortality risk in relation CRP levels did not appreciably change (See Table 7 
Part A) when controlling for adiposity measures.  Most of the adiposity measures were 
associated with increased risk of death in the multivariate models.  Some measures, 
however, were associated with a decreased risk of death.   
Cause-Specific Mortality. Part B of Table 6 includes the odds ratios for CRP level in 
relation to the four outcome groups (Alive, CRC, Other-ORC, and All Other Causes.)  
Due to having more than two outcomes, Polytomous Logistic Regression was employed 
using a referent group consisting of participants with normal CRP level (versus high 
CRP) who were still alive at the end of follow-up which was compared, in parallel, to 
normal-versus-high CRP with respect to each mortality outcome.  Participants with 
elevated CRP levels had a greater than two-fold risk of dying from colorectal cancer 
(2.66 OR, 95% CI=1.28-5.24) compared to participants with normal CRP levels who 
were still alive.  Age adjusted odds ratios for cause-specific mortality among the high-
CRP group were 2.723 (95%CI=1.297-5.719) for death from colorectal cancer, 1.403 
(.810-2.430) for other obesity-related cancers, and 1.619 (1.375-1.906) for the death 
from all other causes.  After adjusting for the same confounders as those in the 
dichotomous logistic regression, individuals with high CRP were two and half times as 
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likely to die from colorectal cancer (2437, 95%CI= 1.203-4.938), 21% more likely to die 
from other obesity-related cancers (1.212, 95%CI= 0.626-2.344), and 30% more likely 
to die from other causes (1.304, 95%CI= 1.059-1.607.) 
Part B of Table 7 shows the odds ratios for cause-specific mortality after adding 
adiposity measures to the multivariate model used above.  Adjustment for BMI indicated 
odds ratios for cause-specific mortality among the high-CRP group of 2.462 (95% 
CI=1.191-5.088) for deaths from colorectal cancer, 1.174 (95% CI= 0.610-2.260 NS) for 
deaths from other obesity-related cancers, and 1.392 (95% CI=1.123-1.725) for death 
from all other causes.  Adjustment for BMI-W resulted in the high-CRP group having a 
2.765 times (95%CI=1.295-5.904) increased risk for death from colorectal cancer, a 26% 
(1.261, 95% CI=0.645-2.63 NS) increased risk for death from other obesity-related 
cancers, and a 42% (1.418; 95% CI= 1.155-1.741) increased risk for death from all other 
causes.  Adjustment for waist circumference resulted in odds ratios of 2.849 
(95%CI=1.313-6.183) for death from colorectal cancer, 1.295 (95% CI=0.672-2.494) for 
death from other obesity-related cancers, and 1.349 (95% CI= 1.099-1.656) for death 
from all other causes.  Finally, after adjusting for waist-to-hip ratio, the odds ratios for 
the individuals in the high-CRP group were found to be 2.867 (95% CI=1.317-6.243) for 
death from colon cancer, 1.214 (95%CI= .621-2.372) for death from other obesity-
related cancers, and 1.302 (95% CI=1.047-1.618.)   
Regarding adiposity as an independent risk factor for all-cause mortality (Table 
8), we found in multivariate analyses that BMIs in the range of overweight and obese 
were significantly associated with reduced risk of death (OR=0.79, 95% CI 0.63-0.99; 
OR=0.65 95% CI 0.52-0.81, respectively.)  Likewise, BMI-W levels tended to be 
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associated with reduced risk of death as was waist circumference in multivariate 
analyses (OR=0.81, 95% CI 0.69-0.94.)  On the other hand, elevated waist-to-hip ratio 
was associated with increased risk of death in both crude and age-adjusted analyses, but 
this effect was attenuated in the multivariate analysis.  When examining adiposity as a 
risk factor for specific causes of death (Table 9), we observed no consistent patterns.  
Surprisingly, in some analyses, data suggested that adiposity may be protective for 
various causes of death.   
 
 
4.0 DISCUSSION 
 
 
4.1 Key Findings 
In this study, we examined the effect of C-reactive protein level on colorectal cancer 
mortality, and if this relationship remained independent of obesity status.  In terms of 
correlates of CRP (Aim 1), we found that individuals with elevated CRP differed from 
individuals with normal CRP in terms of sex, race/ethnicity, alcohol use, physical 
activity level, and personal history of cardiovascular disease and diabetes.  Tobacco use 
marginally different among the two groups (p=.06.)  Age, non-steroidal anti-
inflammatory drug use, and personal history of cancer, however, did not differ 
significantly between the two study groups.  
 We found evidence that individuals with elevated C-reactive protein levels were 
at greater risk for both all-cause mortality and death from colorectal cancer (Aim 2) in 
both univariate and age-adjusted analyses.  An attenuated but still statistically significant 
risk of all-cause mortality and colorectal cancer mortality was maintained in multivariate 
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analyses controlling for logistic regression to account for differences in covariates 
between the two study groups found through study aim 1.  These findings are consistent 
with results reported in a recent study by Heikkila et al. (2009) examining the 
association between CRP and colorectal cancer risk among English men aged 45-59 and 
English women aged 60-80.  
 Consistent with our hypotheses, we found that elevated CRP levels were 
associated with a statistically significant increase in risk of all-cause death and death 
from colorectal cancer independent of obesity status, regardless of which body measure 
of adiposity was analyzed.  Controlling for body mass index, BMI-W, and waist 
circumference yielded slightly attenuated odds ratios, while controlling for waist-to-hip 
ratio slightly increased the odds ratio estimates.   
Very surprisingly, we found either no association of obesity with mortality risk, 
or in some sub-analyses, results suggested that high anthropometric measures of 
adiposity may actually be protective against all-cause mortality and colorectal cancer 
death.  These findings are in stark contrast to the overwhelming preponderance of 
evidence in the literature that states that obesity confers a greater risk of all-cause 
mortality and colorectal cancer mortality.  To further explore these novel findings, we 
compared our findings of the correlates of CRP and adiposity measures with results 
obtained in previous studies.  Correlations between CRP levels and adiposity measures 
performed in previous studies have shown strong positive relationships; however, 
correlations conducted in our investigation yielded much weaker associations.  For 
example, Park et al. (2005) reported Spearman correlation coefficients of 0.69 between 
CRP and BMI, 0.75 between CRP and waist circumference, and 0.68 between CRP 
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and waist-to-hip ratio among an Asian population with no pre-existing inflammatory 
conditions or symptoms.  The correlation between CRP and BMI-W was not performed 
in the study by Park.  Correlations between CRP and adiposity measures in our study 
were much lower, ranging from 0.07 to 0.17.  We speculate that our unusual findings 
may be due to a number of causes.  Park et al. (2005) excluded individuals who had very 
high CRP levels (mg/dL > 10.0), which are indicative of acute infection or trauma.  
Inclusion of these very high values in our study may have resulted in a lack of 
correlation between very high CRP levels and very high adiposity measures, especially 
since those with acute sickness tend to lose body mass over time and exhibit normal or 
even below normal adiposity measurements (Flegal et al., 2007; Manson et al., 2007.)  
To demonstrate the possible effect that the inclusion of individuals with very high CRP 
levels may have had on the correlations, we performed another correlation excluding all 
participants with CRP levels greater than 10 mg/dL.  This exclusion resulted in slightly 
higher correlation coefficients but did not increase them sufficiently to match the 
correlations observed in other studies.  On the other hand, we suspected that the 
preponderance of CRP values labeled as "undetectable" (<.22 mg/dL), that resulted from 
the relative low-sensitivity of the assay used to measure CRP, may have also diluted the 
correlation coefficients.  However, upon exclusion of participants with undetectable 
levels of CRP, we found that the correlation coefficients between adiposity measures and 
CRP became marginally negative.  Although we did not ascertain an explanation of our 
unusual findings with respect to correlation coefficients, the results of the categorical 
analyses between adiposity measures and CRP levels in our study did show statistically 
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significant associations between increased CRP level and increasing adiposity measures. 
 Another possible reason for the null effects of increasing adiposity on mortality 
may be that the increased risk of obesity-related negative outcomes may be eliminated 
by the use of treatment modalities that decrease the negative effects of obesity on one's 
health.  For example, increased use of anti-inflammatory drugs during the follow-up 
period may have distorted the relationship between CRP and obesity measures by 
controlling inflammation brought upon by increased adiposity.  Consistent with this 
hypothesis, Wee et al. (2008) observed CRP levels to be only weakly correlated with 
adiposity measures when a large proportion of the study population was on a low-dose 
NSAID regimen.  Due to the increase in attention by the media advocating use of a low-
dose aspirin regimen for prevention of multiple diseases since baseline data were 
collected, participants that may have started to use NSAIDS during follow-up time may 
not have reported regular NSAID use at baseline.  
A third possible explanation for lack of correlation between CRP and adiposity 
measures is misclassification of adiposity in the NHANES III cohort due to longitudinal 
changes in participants’ obesity levels after the baseline measurement.  In the time 
period following the data collection for NHANES III (1988-1994), there was a 
substantial surge in obesity prevalence throughout the country (CDC, 2008.)  The 
baseline measurements of adiposity, hence, may not accurately represent the obesity 
status of NHANES III individuals during the follow-up period, which occurred between 
6 and 12 years from collection of baseline data.   
If misclassification is at play, is it possible, however, that obesity-related 
sequelae would be manifest so quickly?  Research documenting the effects of weight 
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loss on improved short-term health outcomes provides evidence that alterations in body 
size such as weight gain could have immediate deleterious effects on health.  An 
example of this is the effect seen in a study by Eliassen et al. (2006) among women aged 
30-55 with a mean follow-up time of 24 years that found a 2 kg weight gain since age 18 
conferred a 24.2% greater risk breast cancer (long-term risk), while a 2 kg weight gain 
among the same women within a few years after menopause conferred a 7.6% increase 
in risk of developing breast cancer.  It is possible that many of the NHANES III 
participants whose adiposity measures were “normal” at baseline gained sufficient body 
mass over the course of follow-up to confer increased risk of mortality from obesity-
related diseases such as colorectal cancer.  Therefore, differences in outcomes across the 
study groups converged towards the null.  Misclassification of individuals as having had 
“normal” body size when they should have been characterized as having high adiposity 
later in the study may account for a null or protective effect of increased body size on 
mortality risk. 
We posit that that the hypothesis of misclassification of adiposity measures in 
NHANES III participants is supported by results from a study by Flegal et al. (2007), 
who found that overweight and obesity was a risk factor for deleterious outcomes among 
the NHANES I cohort (1971-75), a longitudinal study with repeated measurements and 
conducted in an earlier and more weight-stable time period yet overweight status was 
found to be a protective factor against death in the NHANES II and III cohorts.  Flegal 
(2007) speculated that a large proportion of the difference between cohorts could be 
explained through increased use of treatment modalities that are superb for managing 
chronic conditions associated with obesity, such as blood sugar-stabilizing drugs for 
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obese diabetics and prophylactic low-dose aspirin use among obese individuals who are 
at risk for inflammation-related diseases such as cardiovascular disease.  On the other 
hand, obesity rates are higher among lower socio-economic classes and the underserved 
(Stunkard et al., 1993.)  Hence, use of beneficial treatments might not fully explain the 
lack of relationship between obesity and mortality observed in the NHANES III cohort. 
It remains unknown to what extent these different hypotheses explain the unusual 
relationships between obesity and mortality risk observed in our study.  We must also 
ask the question about reliability of the participants’ CRP levels over time as well.  CRP 
level is well-known to increase with age and thus follow-up time (Rumley et al., 2006.)  
Furthermore, CRP has been documented to be a marker for both long- and short-term 
mortality risk, while the time-based effects of adiposity and weight gain remain 
inconclusive.  Therefore, it is plausible that relative levels of CRP likely remained 
consistent.  Hence, the risks of all-cause and colorectal cancer-specific mortality 
conferred by high levels of CRP might have remained relatively consistent through 
follow-up period.   
 
    
4.2 Strengths and Limitations 
 
A major strength of this investigation is the use of data from the NHANES III study, a 
complex multi-stage probability sample that is representative of the U.S. population 
enabling generalization of study results to all Americans.  Meticulously constructed 
linkage standards for connecting NHANES III baseline data with National Death Index 
data assured that individuals who were assumed to be alive at the end of follow-up were 
correctly classified.  Furthermore, the comprehensiveness of methods for collecting 
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baseline measurements used in NHANES III lends credence to the reliability of the 
anthropometric measures and lab-assigned values for C-reactive protein (Gunter et al., 
1990; NCHS, 1992.)  Lastly, ample follow-up time (mean=96.5 months) was allotted so 
that a sufficient numbers of deceased participants (n=3384) accrued.   
There are several important limitations to be considered.  First, as discussed, 
NHANES III collected baseline measurements of all variables only once, while more 
reliable findings may have been observed if repeated measurements of the independent 
variables had been accumulated.  This limitation is especially pertinent when analyzing 
adiposity values in the context of a rapidly growing obesity epidemic.   
Another limitation of this study is that only mortality status, not disease 
incidence, was obtained during the follow-up period.  Therefore, the results of this study 
cannot be assumed to reflect risk of colon cancer incidence, which is more common than 
colorectal cancer death and may produce serious quality of life issues independent of 
mortality risk.  Also, the multivariate model might have benefited from inclusion of 
more key risk factors for colorectal cancer death not available in the NHANES III data 
sets we analyzed, such as history of use of statins or dietary history (e.g.,  high red meat 
intake.)  Furthermore, numerous studies have shown that increased CRP and adiposity is 
associated with colon cancer but not significantly associated with rectal or anal cancers 
(MacInnis et al., 2006; Larsson et al., 2007.)  However, mortality data for death from the 
National Death Index was only available for 113 aggregated groups of ICD-10 code 
subgroups.  Only mortality from colorectal cancers (as a group) was available for 
analysis in this investigation.  Therefore, we speculate that the findings in our study may 
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be underestimated when compared to results that would have been observed if only 
death from colon cancer had specifically been analyzed. 
 
4.3  Conclusions 
Findings from this investigation suggest that individuals with high levels of serum C-
reactive protein may have an increased risk of all-cause mortality, colorectal cancer 
death, and death from other obesity-related cancers.  This increased risk seems to persist 
even after adjusting for many potential confounding variables including anthropometric 
measures of adiposity.  We speculate that the negligible change in mortality risk after 
controlling for baseline adiposity status may be due, in part, to increased adiposity of 
participants over time and subsequent misclassification of participants based on baseline 
data.  More research using different study populations is warranted to further investigate 
the links between C-reactive protein, obesity, and colorectal cancer.  Several 
opportunities for future analysis of this topic have been identified: 
1.  Continue to review and analyze extant published findings using NHANES III 
data regarding risk of mortality in relation to adiposity measures to determine 
if our findings are consistent.   
 
2.  Perform survival analyses to identify any differences in the length of time to 
mortality 
      outcomes. 
 
4.  Explore genetic determinants of CRP serum levels among NHANES III 
participants using the restricted-access polymorphism database available 
through the Research Data Center at the National Center for Health Statistics.   
 
5.  Identify an existing longitudinal cohort study in which CRP, obesity status, 
and long-term outcomes can be analyzed.   
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 Further exploration of these topics may provide a greater understanding of the 
inter-relationships of C-Reactive Protein, adiposity measures, and colorectal cancer, 
leading to effective preventive programs that will improve the public health.  
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6.0  FIGURES and TABLES 
Fig. 1   Formation of Study Sample Size in NDI-linked NHANES III Database 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 primary sampling counties 
89 survey locations (nationwide) 
93,653 households screened 
2144 segments 
39,695 persons selected for interview 
31,311 participated in examination & lab 
33,994 persons participated in interview 
7589 persons with NDI follow-up 
7593 persons aged 50+ years 
 
 
 14% non-response 
 
 
 9% non-response 
 
 
 <1% loss to follow-up 
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Fig. 2  Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key:  
  CRC- colorectal cancer 
   oORC= other obesity-other obesity related cancers  
High C-reactive protein 
(>.50 mg/dL; n=2115) 
Normal C-reactive protein 
(<=.50 mg/dL; n=4977) 
NHANES III participants 
aged 50+ with follow-up 
data (n=7589) 
EXPOSURE 
Deceased 
(n=1509) 
Alive 
(n=3468) 
Deceased 
(n=807) 
OUTCOMES 
Deceased- 
CRC 
(n=38) 
Deceased- 
oORC 
(n=67) 
Deceased- 
other 
(n=1402) 
Deceased- 
CRC 
(n=24) 
Deceased- 
oORC 
(n=40) 
Deceased- 
other 
(n=743) 
Alive 
(n=1306) 
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Fig. 3  Classification of the NIHLB BMI-W Index 
 
 
 
BMI-W1 
(disease risk) 
Waist 
Circumference2,3 
 
BMI3 
 
BMI Label3 
 
Average (1) Any < 18.5 Underweight (1)  
 Any 18.5-24.9 Normal (2)  
Increased (2) Normal 25.0-29.9 Overweight (3)  
High (3) High  25.0-29.9 Overweight (3) 
 Normal  30.0-34.9 Obese I (4) 
Very High (4) High 30.0-34.9 Obese I (4)  
 Any  35.0-39.9 Obese II (5) 
Extremely High (5) 
 Any 40.0+ Obese III (6) 
 
 
1. High waist circumference defined as: Males > 40 in (102 cm); Females > 35 in (88 cm) 
2. National Institutes of Health, Expert Panel.  Executive summary of the clinical 
guidelines on the identification, evaluation, and treatment of overweight and obesity 
in adults.  Arch Intern Med. 199;158(17):1855-67. 
3. Balkau B, Charles MA, Drivsholm T, et al. Frequency of the WHO metabolic 
syndrome in European cohorts, and an alternative definition of an insulin 
resistance syndrome.  Diabetes Metab 2002;28(5):364-376. 
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Table 1 Participant Characteristics according to C-Reactive Protein Level 
 
C-Reactive Protein 
        Normal                        High 
      (n=4977)                    (n=2115) 
Chi-sq2 p-Value 
Sex 
Male 
Female  
  2457 (76.71)1 
2520 (70.66) 
940 (23.29) 
1175 (29.34) 
 
11.46 
 
.0007 
Race/Ethnicity 
     Non-Hispanic White1 
     Non-Hispanic Black 
     Mexican American 
     Other 
 
2925 (74.25)  
897 (61.99) 
963 (71.07) 
192 (78.24) 
 
1104 (25.75) 
534 (38.01) 
418 (28.93) 
59 (21.76) 
 
 
 
 
23.96 
 
 
 
 
<.0001 
Age  
   Mean (SD) 
 
67.79 (10.76) 
 
68.00 (10.63) 
 
-0.772 
 
.4426 
Age 
  50-54 
   55-59 
   60-64 
   65-69 
   70-74 
   75-79 
     80+ 
 
656 (75.11) 
 617 (74.73) 
806 (73.09) 
739 (73.02) 
741 (72.50) 
474 (72.31) 
944 (70.89) 
 
257 (24.89) 
253 (25.27) 
360 (26.91) 
333 (26.98) 
310 (27.50) 
198 (27.69) 
404 (29.11) 
 
 
 
 
 
 
 
3.79 
 
 
 
 
 
 
 
.7056 
Smoking Status 
   Never  
   Past   
   Current  
 
2332 (75.39) 
1799 (72.54) 
846 (70.67) 
 
893 (24.61) 
771 (27.46) 
451 (29.33) 
 
 
 
5.68 
 
 
 
.0585 
Alcohol Use 
   Never  
   Past  
   Current  
 
988 (71.52) 
2015 (71.33) 
1657 (77.12) 
 
437 (28.48) 
932 (28.67) 
565 (22.88) 
 
 
12.40 
 
 
.0020 
Physical Activity Level 
  More active than others  
  About the same as others 
  Less active than others  
   
 
1971 (80.91) 
2045 (71.42) 
816 (61.09) 
 
 
568 (19.09) 
938 (28.58) 
554 (38.31) 
 
 
 
99.43 
 
 
<.0001 
Current NSAID use 
  Yes  
   No  
 
3354 (72.79) 
1578 (74.83) 
 
1449 (27.21) 
650 (25.17) 
 
2.38 
 
.1233 
Positive Personal History  
   Cancer  
   Cardiovascular Disease  
   Diabetes  
 
764 (73.18) 
767 (63.35) 
612 (61.60) 
 
315 (28.81) 
475 (36.65) 
421 (38.40) 
 
0.02 
31.65 
31.59 
 
.8886 
<.0001 
<.0001 
1  n(%); percentages are weighted and rounded. 
2 Rao-Scott Chi-square used to correct for weighted frequencies except for age as a 
continuous variable, where t-test is used. 
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Table 2  Adiposity Measures according to C-Reactive Protein Level  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1  n(%); percentages are weighted and rounded. 
2  Rao-Scott Chi-square used to correct for weighted frequencies. 
3  High waist circumference >= 102 cm for men, >= 88 cm for women 
4 Body Mass Index stratified by waist circumference (BMI-W) 
5 High waist-to-hip ratio >= 1.0 for men, >=0.9 for women 
 
 
  
 
C-Reactive Protein 
Chi-sq2 p-Value Normal 
n= 4843 
High 
n=2063 
Body Mass Index 
Normal 
Overweight 
Obese 
 
1803 (82.16)1 
1990 (75.13) 
1050 (59.86) 
 
498 (17.84) 
786 (24.87) 
779 (40.14) 
 
 
 
149.05 
 
 
 
<.0001 
Waist Circumference3 
Normal  
High  
 
2453 (81.82) 
2376 (66.65) 
 
722 (18.18) 
1314 (33.35) 
 
 
85.17 
 
 
<.0001 
BMI-W4 
1- Normal  
2- Elevated  
3- High 
4- Very High  
5- Extremely High  
 
1803 (82.16) 
828 (82.09) 
1141 (70.64) 
932 (62.83) 
62 (32.46) 
 
498 (17.84) 
260 (17.91) 
526 (29.36) 
620 (37.17) 
120 (67.54) 
 
 
 
 
 
186.72 
 
 
 
 
 
<.0001 
Waist-to-Hip Ratio5 
Normal  
High  
 
2141 (78.79) 
2585 (69.66) 
 
745 (21.21) 
1216 (30.34) 
 
 
28.80 
 
 
<.0001 
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Table 3  Correlations1 between C-Reactive Protein and Adiposity Measures  
 
 
     1 Spearman correlations for ordinal data 
       2 Body Mass Index stratified by waist circumference (BMI-W) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Table 4   Participant Characteristics and All-Cause Mortality 
 C-Reactive Protein 
 
P-Value 
 
Body Mass Index 
   
 
0.17 <.0001 
 
BMI-W2 
 
0.19 <.0001 
 
Waist Circumference 
 
0.14 <.0001 
 
Waist-to-Hip Ratio 
 
0.07 <.0001 
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1 n (%); weighted and rounded percentages. 
2 Rao-Scott Chi-square used to correct for weighted frequencies except for age as a continuous variable, where t-test is used. 
3 BMI I<18.5 not included in analyses 
4 Body Mass Index stratified by waist circumference (BMI-W), 
5High waist circumference >= 102 cm for men, >= 88 cm for women 
6 High waist-to-hip ratio >= 1.0 for men, >=0.9 for women 
7SE= Standard Error of the Mean  
Table 5- Participant Characteristics and Cause-Specific Mortality 
 Alive n=5022  
Deceased 
n=2567  Chi-Square
2 P-Value 
Sex 
   Male  
   Female  
 
2237 (73.12)1 
2785 (76.49) 
 
1378 (26.88)1 
1189 (23.51) 
 
7.04 
 
.0080 
Race/Ethnicity 
   Non-Hispanic White  
   Non-Hispanic Black  
   Mexican American  
   Other  
 
2645 (74.37) 
1076 (69.26) 
1075 (81.29) 
226 (89.06) 
 
1621 (25.63) 
544  (30.74) 
362 (18.71) 
40 (10.94) 
 
 
50.96 
 
 
<.0001 
Age at Interview 
    Mean (SD) 
 
64.47 (9.38) 
 
75.14 (9.77) 
 
-46.222 
 
<.0001 
Age at Interview 
   50-54 
   55-59  
   60-64  
   65-69 
   70-74  
   75-79 
   80+  
 
872 (93.45) 
794 (88.34) 
1013 (84.93) 
833 (75.13) 
743 (69.59) 
363 (51.74) 
404 (29.21) 
 
78 (6.55) 
124 (11.66) 
216 (15.07) 
304 (24.87) 
382 (30.41) 
378 (48.26) 
1085 (70.79) 
 
 
 
712.68 
 
 
 
<.0001 
 
Body Mass Index3 
   Normal (18.5-24.9) 
   Overweight (25.0-29.9) 
   Obese (30.0+) 
 
1500 (72.12) 
196 (76.07) 
1481 (80.17) 
 
975 (27.88) 
950 (23.93) 
480 (19.83) 
 
 
24.58 
 
 
<.0001 
 
BMI-W4 
   1- Normal 
   2- Elevated 
   3- High 
   4- Very high 
   5- Extremely high 
 
1516 (72.12) 
767 (76.24) 
1202 (76.95) 
1253 (81.00) 
158 (80.20) 
 
1039 (27.88) 
378 (23.76) 
547 (23.05) 
393 (19.00) 
44 (19.80) 
 
 
 
37.95 
 
 
 
<.0001 
Waist Circumference5   
   Normal 
   High 
 
2111 (72.97) 
2786 (78.25) 
 
1303 (27.03) 
1118 (421.75) 
 
20.64 
 
<.0001 
Waist-to-Hip Ratio6 
   Normal  
   High 
 
2026 (76.53) 
2780 (75.99) 
 
1106 (23.47) 
1185 (24.01) 
 
.13 
 
.7202 
C-reactive Protein (mg/dL)  
   Normal- (<0.5)  
   Elevated- (>0.5) 
 
3468 (78.25) 
1306 (69.38) 
 
1509 (21.74) 
807 (30.62) 
 
42.62 
 
<.0001 
Smoking Status 
   Never  
   Past  
   Current  
 
2374 (77.65) 
1718 (73.36) 
930 (72.37) 
 
1080 (22.35) 
1028 (26.64) 
459 (27.63) 
 
13.57 
 
.0011 
Alcohol Use 
   Never  
   Past  
   Current  
 
981 (73.23) 
2041 (72.58) 
1734 (82.29) 
 
546 (26.77) 
1065 (27.43) 
563 (17.41) 
 
49.80 
 
<.0001 
Physical Activity Level 
    More active than others 
     About the same as others  
Less active than others 
 
1896 (79.76) 
2150 (76.37)  
854 (62.93) 
 
782 (20.24) 
1022 (23.63) 
667 (37.07) 
 
64.75 
 
<.0001 
Current NSAID use 
   Yes 
   No  
 
3404 (75.66) 
1580 (73.26) 
 
1697 (24.34) 
842 (26.74) 
 
2.79 
 
.0950 
Positive Personal History     
Cancer 
   Cardiovascular Disease  
   Diabetes  
 
602 (14.22) 
593 (9.90) 
595 (9.00) 
 
550 (24.02) 
772 (28.32) 
510 (17.56) 
 
51.57 
428. 67 
76.53 
 
<.0001 
<.0001 
<.0001 
Follow-up Time in Months 
   Mean (SE)7 
   Median 
 
108.60 (20.58) 
108.00 
 
58.45 (34.42) 
66.00 
 
79.202 
 
<.0001 
 Alive 
(n=5028) 
Deceased-
CRC 
(n=68) 
Deceased- oORC 
(n=122) 
Deceased-Other 
(n=2375) 
 
Chi-sq2 
 
P-Value 
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1 n (%); weighted and rounded percentages. 
2 Rao-Scott Chi-Square Test for weighted sample data 
3 BMI I<18.5 not included in analyses 
4 Body Mass Index stratified by waist circumference (BMI-W), 
5High waist circumference >= 102 cm for men, >= 88 cm for women 
6 High waist-to-hip ratio >= 1.0 for men, >=0.9 for women 
7SE= Standard Error of the Mean 
§ values can not be obtained due to empty cells 
Sex 
   Male 
   Female 
 
2238 (73.13)1* 
2790 (76.53) 
 
46 (0.64)1* 
22 (0.53) 
 
77 (1.39)1* 
45 (0.98) 
 
1254 (24.84)1* 
1121 (21.96) 
8.27 .0408 
Race/Ethnicity 
   Non-Hispanic White  
   Non-Hispanic Black 
   Mexican American 
   Other 
 
2649 (74.40) 
1076 (69.26) 
1077 (81.31) 
226 (89.06) 
 
37 (0.55) 
20 (1.14) 
11 (0.76) 
0 (0.00) 
 
78 (1.18) 
33 (1.66) 
9 (0.46) 
2 (0.50) 
 
1504 (23.87) 
491 (27.93) 
342 (17.48) 
38 (10.44) 
§ § 
Age 
   Mean (SD) 
 
64.49 (9.40) 
 
73.06 (9.10) 
 
74.42 (10.00) 
 
75.23 (9.77) § § 
Age Group 
   50-54 
   55-59 
   60-64 
   65-69 
   70-74 
   75-79 
   80+ 
 
873 (93.45) 
794 (88.34) 
1013 (84.93) 
833 (75.13) 
743 (69.59) 
363 (51.74) 
409 (29.72) 
 
2 (0.06) 
5 (0.35) 
3 (0.16) 
15 (0.92) 
13 (0.91) 
8 (0.89) 
22 (1.32) 
 
3 (0.14) 
8 (0.84) 
14 (0.99) 
16 (1.51) 
16 (1.29) 
18 (1.67) 
47 (2.71) 
 
73 (6.34) 
111 (10.46) 
199 (13.92) 
273 (22.44) 
353 (28.22) 
352 (45.70) 
1014 (66.25) 
 
935.52 <.0001 
Body Mass Index3 
Normal 
Overweight 
Obese 
 
1503 (72.18) 
1967 (76.08) 
482 (80.17) 
 
27 (0.78) 
26 (0.46) 
13 (0.52) 
 
46 (1.23) 
50 (1.38) 
23 (0.84) 
 
900 (25.81) 
874 (22.07) 
23 (18.47) 
31.96 
 
<.0001 
 
BMI-W4 
   1- Normal 
   2- Elevated 
   3- High 
   4- Very High 
   5- Extremely High 
 
1503 (72.18) 
768 (76.27) 
1202 (76.95) 
1254 (81.01) 
158 (80.20) 
 
27 (0.78) 
15 (0.61) 
11 (0.36) 
11 (0.57) 
2 (0.39) 
 
46 (1.23) 
27 (2.09) 
22 (0.85) 
19 (0.86) 
3 (0.97) 
 
900 (25.81) 
336 (21.02) 
514 (21.84) 
363 (17.57) 
39 (18.44) 
48.79 
 
<.0001 
 
Waist Circumference5 
   Normal  
   High 
 
2115 (73.03) 
2788 (78.26) 
 
38 (0.61) 
28 (0.53) 
 
69 (1.52) 
51 (0.88) 
 
1194 (24.84 
1039 (20.34 
23.37 <.0001 
Waist-to-hip Ratio6 
   Normal  
   High 
 
2031 (76.59) 
2781 (75.99) 
 
32 (0.64) 
30 (0.45) 
 
61 (1.32) 
54 (1.06) 
 
1011 (21.46) 
1101 (22.51) 
2.10 .5523 
C-reactive Protein (mg/dL) 
   Normal  
   High 
 
3470 (78.27) 
1308 (69.38) 
 
38 (0.41) 
24 (0.97) 
 
67 (1.03 
40 (1.26) 
 
1402 (20.28) 
743 (28.38) 47.01 <.0001 
Smoking Status 
   Never 
   Past 
   Current 
 
2378 (77.68) 
1720 (73.40) 
930 (72.37) 
 
29 (0.49) 
28 (0.74) 
11 (0.44) 
 
58 (1.29) 
45 (0.83) 
19 (1.56) 
 
991 (20.55) 
955 (25.02) 
429 (25.63) 
23.90 .0005 
Alcohol Use 
   Never  
   Past 
   Current 
 
981 (73.23) 
2043 (72.60) 
1736 (82.60) 
 
14 (0.62) 
30 (0.67) 
22 (0.54) 
 
24 (0.94) 
47 (1.11) 
26 (0.94) 
 
508 (25.21) 
987 (25.63) 
514 (15.92) 
71.13 <.0001 
Physical Activity Level 
   More active than others  
   Less active than others 
   About the same as others 
 
1897 (79.78) 
856 (32.98) 
2153 (76.40) 
 
21 (0.43) 
9 (0.35) 
33 (0.73) 
 
42 (0.98) 
30 (1.55) 
48 (1.24) 
  
718 (18.82) 
628 (35.12) 
940 (21.63) 
97.43 <.0001 
Current NSAID use 
Yes     
No 
 
3407 (75.68) 
1583 (73.29) 
 
49 (0.60) 
19 (0.54) 
 
83 (1.08) 
39 (1.42) 
 
1564 (22.64) 
783 (24.76) 
 
4.43 
 
<.0001 
Positive Personal History    
Cancer     
Cardiovascular Disease 
Diabetes 
 
603 (14.22) 
596 (9.96) 
596 (9.02) 
 
25 (33.60) 
14 (18.62) 
11 (11.66) 
 
45 (41.05) 
24 (12.44) 
17 (11.70) 
 
479 (22.91) 
734 (29.38) 
482 (18.01) 
 
83.79 
300.87 
102.23 
 
<.0001 
<.0001 
<.0001 
Follow-up time in Months 
Mean (SE)7 
Median 
 
108.43 (1.47) 
108.00 
 
58.31 (4.65) 
57.00 
 
55.42 (4.02) 
52.00 
 
61.07 (1.57) 
57.00 
 
§ 
 
§ 
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Table 6  Crude, Age-adjusted, and Multivariate-adjusted Odds Ratios for Mortality in relation to C-reactive Protein Level  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Adjusted for age, sex, race/ethnicity, tobacco use alcohol use, physical activity level, NSAID use, personal history of cancer, personal history of CVD, personal history of diabetes 
2 Referent group:  Participants with normal CRP levels who were alive at the end of the study 
3 CRC= Colorectal Cancer 
4  oORC= Other Obesity-Related Cancer (i.e., breast, endometrial, pancreatic, prostate) 
 n Crude Odds Ratio  (95% CI) 
Age-adjusted OR 
 (95% CI) 
Multivariate-adjusted OR1 
(95% CI) 
C-Reactive Protein 
Normal 
High 
 
4977 
2115 
 
 
1.0 
1.589 (1.388-1.819) 
 
 
1.0 
1.628 (1.388-1.909) 
 
1.0 
1.318 (1.080-1.610) 
 
C-Reactive Protein  
Alive w/normal CRP2 
CRC3 
Other ORC4 
All Other Causes 
 
 
3470 
24 
40 
743 
 
 
--- 
2.660 (1.277-5.539) 
1.378 (0.798-2.380) 
1.579 (1.373-1.816) 
 
 
--- 
2.723 (1.297-5.719) 
1.403 (0.810-2.430) 
1.619 (1.375-1.906) 
 
 
--- 
2.437 (1.203-4.938) 
1.212 (0.626-2.344) 
1.304 (1.059-1.607) 
 
 
 
A 
 
 
 
 
 
B 
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Table 7  Addition of Adiposity Measures into Multivariate Models estimating Odds Ratios for All-Cause Mortality and     
              Cause-Specific Mortality in relation to C-Reactive Protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Adjusted for age, sex, race/ethnicity, tobacco use alcohol use, physical activity level, NSAID use, personal history of cancer, personal history of CVD, personal history of diabetes. 
2 Body Mass Index (BMI), Body Mass Index stratified by waist circumference (BMI-W), Waist Circumference (WC), Waist-Hip-Ratio (WHR) 
3 Referent group:  Participants with normal CRP levels who were alive at the end of the study 
4 CRC= Colorectal Cancer 
5 o-ORC= Other Obesity-related Cancer (i.e., breast, endometrial, pancreatic, prostate) 
 
 n BMI-adjusted OR
1,2 
 (95%CI) n 
BMI-W adjusted OR1,2  
(95%CI) n 
WC-adjusted OR1,2  
(95%CI) n 
WHR-adjusted OR1,2  
(95%CI) 
C-Reactive Protein  
Normal 
High 
6201 
 
1.0 
1.407 (1.140-1.736) 
 
6099 
 
1.0 
1.438 (1.175-1.759) 
 
6146 
 
1.0 
1.375 (1.127-1.678) 
6011 
 
1.0 
1.325 (1.073-1.636) 
C-Reactive Protein  
Alive w/ Normal CRP3 
CRC4 
o-ORC5 
All Other Causes 
6201 
 
--- 
2.462 (1.191-5.088) 
1.174 (0.610-2.260) 
1.392 (1.123-1.725) 
6099 
 
--- 
2.765 (1.295-5.904) 
1.261 (0.645-2.463) 
1.418 (1.155-1.741) 
6146 
 
--- 
2.849 (1.313-6.183) 
1.295 (0.672-2.494) 
1.349 (1.099-1.656) 
6011 
 
--- 
2.867 (1.317-6.243) 
1.214 (0.621-2.372) 
1.302 (1.047-1.618) 
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                    Table 8  Odds Ratios for All-Cause Mortality in relation to Adiposity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1   Adjusted for age, sex, race/ethnicity, tobacco use alcohol use, physical activity level, NSAID use, personal history of cancer, personal history of CVD,  
    personal history  of diabetes, and CRP level. 
2    Body Mass Index stratified by waist circumference (BMI-W)  
 
 
 
 
 
 n Crude OR (95% CI) 
Age-adjusted OR 
(95% CI) 
Adjusted OR1  
(95% CI) 
BMI 
Normal 
Overweight  
Obese 
6200 
 
 
 
1.0 
0.814 (0.692-0.957) 
0.640 (0.539-0.759) 
 
1.0 
0.913 (0.754-1.105) 
0.910 (0.760-1.089) 
 
1.0 
0.791 (0.627-0.997) 
0.650 (0.521-0.811) 
 
BMI-W2 
   Normal 
   Elevated 
   High 
   Very High 
   Extremely High 
6098 
 
 
 
1.0 
0.806 (0.649-1.002) 
0.775 (0.651-0.922) 
0.607 (0.511-0.721) 
0.639 (0.407-1.003) 
 
1.0 
0.989 (0.772-1.266) 
0.838 (0.688-1.021) 
0.859 (0.713-1.036) 
1.130 (0.680-1.878) 
 
1.0 
0.784 (0.564-1.092) 
0.759 (0.598-0.963) 
0.633 (0.505-0.792) 
0.634 (0.314-1.283) 
 
Waist Circumference 
Normal 
High 
6145  
1.0 
1.031 (0.874-1.216) 
 
1.0 
0.986 (0.817-1.189) 
 
1.0 
0.806 (0.688-0.944) 
Waist-to-hip Ratio 
Normal 
High 
6010  
1.0 
1.589 (1.388-1.819) 
 
 
1.0 
1.628 (1.388-1.909) 
 
1.0 
1.008 (.814-1.249) 
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Table 9   Odds Ratios for Cause-Specific Mortality in relation to Adiposity  
 
 
1 Adjusted for age, sex, race/ethnicity, tobacco use alcohol use, physical activity level, NSAID use, personal history of 
          cancer, personal history of CVD, personal history of diabetes, and CRP level. 
2  Referent group  
3 CRC= Colorectal Cancer 
4 o-ORC= Other Obesity-related Cancer (i.e., breast, endometrial, pancreatic, prostate) 
5 Body Mass Index stratified by waist circumference (BMI-W) 
 n Crude Odds Ratio (95% CI) 
Age-adjusted 
OR (95% CI) 
Multivariate 
OR1 
(95% CI) 
Body Mass Index: Overweight 
Alive with Normal BMI2 
CRC3 
o-ORC4 
All Other Causes 
 
Body Mass Index: Obese 
Alive and Normal BMI2 
CRC 
o-ORC 
All Other Causes 
7355 
--- 
0.556 (0.275-1.123) 
1.066 (.639-1.778) 
0.811 (0.684-0.963) 
 
 
--- 
0.600 (0.271-1.327) 
0.612 (0.295-1.270) 
0.644 (0.542-0.766) 
 
--- 
0.617 (0.299-1.275) 
1.170 (.692-1.980) 
0.912 (0.747-1.113) 
 
 
--- 
0.828 (0.357-1.921) 
0.816 (0.392-1.699) 
0.922 (0.468-1.106) 
 
--- 
0.427 (0.208-0.889) 
1.024 (.548-1.912) 
0.798 (0.639-0.996) 
 
 
--- 
0.663 (0.259-1.696) 
0.756 (0.345-1.654) 
0.781 (0.631-0.968) 
Waist Circumference 
         Alive with Normal WC2 
CRC 
         o-ORC 
         All Other Causes 
 
7322 
--- 
0.807 (0.407-1.602) 
0.538 (0.324-0.896) 
0.764 (0.677-0.862) 
--- 
0.871 (0.428-1.774) 
0.577 (0.346-0.960) 
0.838 (0.731-0.961) 
--- 
0.810 (0.329-1.996) 
0.684 (0.375-1.246) 
0.883 (0.760-1.025) 
BMI-W5 Elevated 
         Alive and Normal BMI-W2 
CRC 
o-ORC 
        All Other Causes 
 
BMI-W High 
         Alive with Normal BMI-W2 
CRC 
o-ORC 
        All Other Causes 
 
BMI-W Very High 
         Alive with Normal BMI-W2 
CRC 
o-ORC 
         All Other Causes 
 
BMI-W Extremely High 
         Alive with Normal BMI-W2 
CRC 
o-ORC 
        All Other Causes 
7220 
 
--- 
0.740 (0.329-1.666) 
1.606 (0.874-2.954) 
0.771 (0.611-0.972) 
 
 
--- 
0.435 (0.185-1.020) 
0.648 (0.341-1.230) 
0.794 (0.663-0.950) 
 
 
--- 
0.647 (0.284-1.475) 
0.621 (0.302-1.277) 
0.607 (0.509-0.723) 
 
 
--- 
0.452 (0.087-2.352) 
0.710 (0.105-4.776) 
0.643 (0.404-1.024) 
 
--- 
0.894 (0.388-2.059) 
1.920 (1.029-3.589) 
0.942 (0.725-1.224) 
 
 
--- 
0.467 (0.195-1.122) 
0.691 (0.361-1.325) 
0.862 (0.703-1.056) 
 
 
--- 
0.893 (0.371-2.146) 
1.144 (0.680-1.926) 
1.156 (0.163-8.202) 
 
 
---- 
0.766 (0.138-4.236) 
1.156 (1.101-1.125) 
1.144 (0.680-1.926) 
 
--- 
0.500 (0.244-1.026) 
1.381 (0.563-3.386) 
0.728 (0.521-1.019) 
 
 
--- 
0.397 (0.158-1.002) 
0.740 (0.379-1.446) 
0.792 (0.633-0.991) 
 
--- 
0.672 (0.261-1.730) 
0.797 (0.362-1.757) 
0.751 (0.604-0.933) 
 
 
--- 
0.810 (0.111-5.890) 
0.145 (0.028-0.743) 
0.895 (0.445-1.798) 
 
Waist-to-Hip Ratio 
         Alive with Normal WHR2 
CRC 
o-ORC 
        All Other Causes 
7101 
 
--- 
0.711 (0.351-1.438) 
0.809 (0.515-1.272) 
1.057 (0.893-1.252) 
 
--- 
0.680 (0.330-1.402) 
0.770 (0.490-1.209) 
1.016 (0.838-1.231) 
 
--- 
0.547 (0.258-1.158) 
0.929 (0.523-1.650) 
1.054 (0.860-1.291) 
 
